For a long time, the treatment of malignant solid tumors has adopted the traditional treatment model based on surgery. With the emergence of a large amount of evidence-based medical evidence, more and more scholars have realized that tumor is a systemic disease, and single treatment often cannot achieve good results, and only multidisciplinary comprehensive treatment can achieve better efficacy. Modern tumor treatment has entered the era of integrated clinical multidisciplinary treatment. Integrated treatment model has been commonly used in solid tumor treatment Clinical multidisciplinary work team (MDT) has become an important model of disease treatment in large hospitals abroad. Some important oncology treatment centers in the United States and other countries have established MDT treatment models. In Germany, MDT model has become an important part of hospital medical system. The integrated treatment model of malignant tumors in China has also penetrated into several tumor treatment fields. Currently, the multidisciplinary integrated treatment model is best implemented in the field of breast cancer and lung cancer. Pre-operative neoadjuvant therapy for early breast cancer patients has significantly increased the rate of breast-conserving surgery; while adjuvant radiotherapy after breast-conserving surgery is an important means to prevent patients from recurrence and metastasis after surgery, and for early breast cancer patients with positive HER2 test using targeted drugs – -Trastuzumab adjuvant therapy can significantly reduce the risk of recurrence and death. For non-small cell lung cancer, surgery and post-operative adjuvant chemoradiotherapy for early stage lung cancer are the basic treatment tools. The 2010 NCCN gastric cancer guidelines also continue the emphasis on multidisciplinary treatment, with the NCCN panel suggesting that “multidisciplinary treatment decisions should be encouraged from all disciplines involved in the treatment of the patient”. Postoperative adjuvant radiotherapy is the most common modality for the comprehensive treatment of colorectal cancer, and was one of the first modalities used for locally advanced colorectal cancer. Other common malignancies also have integrated treatment modalities applied. Overview of various treatment methods for hepatocellular carcinoma Hepatocellular carcinoma (HCC) is one of the malignant tumors that seriously threaten the health of our people. 2010 National Health Ministry statistical synopsis shows that HCC ranks the second cause of death from malignant tumors in China, after lung cancer. However, due to the insidious onset and rapid progression of HCC, most patients are already in the middle and late stages when diagnosed, missing the best time for treatment, so the overall prognosis is poor, with an overall median survival of only 3-6 months. Surgical treatment Surgical resection is currently the most effective treatment for early stage HCC patients, however, due to the combination of chronic hepatitis and cirrhosis (85%) in most HCC patients in China, long-term chronic liver disease leads to poor compensatory capacity of liver function, the resectable rate of tumor is only 10-37%, and the recurrence rate after surgery is high (50%-60%). Liver transplantation Liver transplantation is another curable treatment technique for HCC other than partial hepatectomy, and is the only curative option for end-stage liver disease. However, the strict indications for liver transplantation, the difficulty of donor liver, the tendency of intrahepatic recurrence, the huge medical costs, and the opportunistic infections caused by the application of immunosuppressive drugs make it difficult to promote liver transplantation for HCC. Obviously, postoperative recurrence and metastasis are the greatest obstacles limiting the efficacy of HCC surgery. Hepatic artery cannulation with chemotherapy (TACE) Currently, TACE is the main treatment for HCC that cannot be surgically resected. However, due to the establishment of collateral circulation and the existence of portal blood supply after arterial embolization, it is difficult to completely necrotize tumor cells by simple TACE, especially in the periphery of the tumor, pericyclic and extrapericyclic invasion, subfoci and other areas where portal vein is the main blood supply, cancer cells commonly remain after TACE and become a source of recurrence. Therefore, TACE treatment has only palliative effect and the long-term efficacy is not satisfactory.